Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00401401
Status:
TERMINATED
Last Update Posted:
2011-12-23
First Post:
2006-11-17
Brief Title:
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
Sponsor:
Genmab
Organization:
Genmab
Study Overview
Official Title:
An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design1 Investigating Zalutumumab an Anti-EGF Receptor Antibody in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck 1 The Parallel Group Part Was Cancelled
Status:
TERMINATED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
MTD was established and patients completed 16 months safety f-up and response assessments It is considered of limited value to follow patients for 3 years
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None